author-photo

Barry Skikne

Bristol-Myers Squibb

4

Papers

6

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)